CD274 and gastric cancer: Although direct clinical data in gastric cancer are pending, the pronounced immunomodulatory effects observed with Axl blockade in other tumor models—restoring T-cell presence, lowering checkpoint ligand expression, and improving response to PD-1/PD-L1 therapy—strongly support clinical exploration of this combination strategy in GC.